Unstimulated / (Left panel) and 10 μg/ml phytohemagglutinin (PHA)-stimulated (2 days) / (Right panel) peripheral blood mononuclear cells were stained with Alexa Fluor® 647 Mouse Anti-Human CD3 and FITC Mouse Anti-Human CD134 Antibody at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD134 |
Synonyms | Tumor necrosis factor receptor superfamily member 4; ACT35 antigen; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; TXGP1L; TNFRSF4 |
Location | Membrane |
Accession | P43489 |
Clone Number | S-R589 |
Antibody Type | Mouse mAb |
Isotype | IgG1,k |
Application | FCM |
Reactivity | Hu |
Positive Sample | Human peripheral blood mononuclear cells |
Purification | Protein G |
Concentration | 0.2 mg/ml |
Conjugation | FITC |
Physical Appearance | Liquid |
Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD134, also known as OX40 or tumor necrosis factor receptor superfamily member 4 (TNFRSF4), is a type 1 transmembrane glycoprotein and a secondary co-stimulatory immune checkpoint molecule involved in long-term T cell immunity. It is transiently expressed on activated CD4+ and CD8+ T cells after T cell receptor (TCR) ligation. The interaction between CD134 and its ligand, OX40L, enhances T cell activation, proliferation, survival, and cytokine production. CD134 is crucial for maintaining an immune response beyond the initial activation phase and is being investigated as a target in cancer immunotherapy, autoimmune disease modulation, and vaccine development.
Picture
Picture
FC
